A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
PHASE2
The purpose of this study is to evaluate the effectiveness and safety of re...
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
PHASE1
This is a Phase 1B study assessing the safety of immune checkpoint inhibiti...
Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma
NA
This is a monocentric, prospective study evaluating the effectiveness in re...
Status
Recruiting
Location
Istituto Nazionale Tumori IRCCS - Fondazione "G. Pascale"